Journals / Selçuk Tıp Dergisi / 2009 / Cilt: 25 - Sayı: 2

Asymmetric dimethyl arginine and its clinical implication

Asimetrik dimetilarjinin ve klinik önemi

Pages
107–115
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Strategies to reduce plasma ADMA levels may be a new approach in therapeutic applications in endothelial dsyfunction-related disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asymmetric Dimethyl Arginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase and causes local vasospasm and endothelial dysfunction by inhibiting local NO production.
📊
Key Findings & Data:Elevated plasma ADMA levels have been demonstrated in patients with coronary artery disease, hypertension, cor pulmonale, stroke, renal failure, alzheimer and hyperhomocysteinemia.
💡
Conclusion & Impact:Strategies to reduce plasma ADMA levels may be a new approach in therapeutic applications in endothelial dsyfunction-related disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Nitrik oksit sentaz · Nitric Oxide Synthase

Abstract

Asymmetric Dimethyl Arginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase and causes local vasospasm and endothelial dysfunction by inhibiting local NO production. Therefore ADMA is evaluated as a secondary risk factor for coronary artery disease. This article will review; a) ADMA synthesis and catabolism, b) relationship of ADMA with various physiological and pathophysiological conditions and c) clinical application areas. Atherosclerosis development is a complex process and endothelial dysfunction plays a crucial role in patients with coronary atherosclerosis. Elevated endogenous NO synthase inhibitor ADMA levels represent a novel risk factor for the development of endothelial dysfunction. Elevated plasma ADMA levels have been demonstrated in patients with coronary artery disease, hypertension, cor pulmonale, stroke, renal failure, alzheimer and hyperhomocysteinemia. Strategies to reduce plasma ADMA levels may be a new approach in therapeutic applications in endothelial dsyfunction-related disease.

Özet

Asimetrik dimetil arginin (ADMA) endojen Nitrik Oksit sentaz inhibitörüdür. Lokal Nitrik Oksit (NO) sentezini engelleyerek vazospazma ve endotel disfonksiyonuna neden olmakta ve koroner arter hastalık gelişimi için risk faktörü olarak kabul edilmektedir. Bu makalede ADMA sentezi, yıkımı, çeşitli fizyolojik ve patofizyolojik olaylardaki düzeyi ve klinik kullanım alanları irdelenecektir. Ateroskleroz gelişim süreci kompleks bir süreçtir ve multifaktöryel nedenlere dayanmaktadır. Artmış kan basıncı etyolojisinde, NO sentezindeki azalma ile seyreden vazokonstriksiyon önemli rol oynamaktadır. Yine endotel disfonksiyonunda azalmış NO düzeyleri önemli etkilere sahiptir. Endotel disfonksiyonu kronik bir süreç sonucu gelişmekte ve bu sürece katkıda bulunan parametreler önemli risk faktörü olarak değerlendirilmektedir. NO sentezini azaltan ADMA’nın endojen bir inhibitör molekül oluşu son zamanlarda ADMA üzerine olan çalışmaları yoğunlaştırmıştır. Yüksek ADMA düzeylerinin renal hastalıklarla, preeklampsi, Alzheimer, siroz, cor pulmonale ile ilişkili olduğu gözlemlenmiştir. Endotel disfonksiyonunun önemli nedenlerinden biri olan ADMA düzeylerini azaltmaya yönelik stratejiler, ilgili hastalıkların tedavisinde yeni yaklaşımlara yol açabilir.

🔖

Cite This Article

ERDEM, S., ÜNLÜ, A. (2009). Asymmetric dimethyl arginine and its clinical implication. Selçuk Tıp Dergisi, Cilt: 25 - Sayı: 2, 107–115. https://ajindex.com/articles/319540

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Clarke S. Protein methylation. Curr Opin Cell Biol 1993;5:977–983
  2. McBride AE, Silver PA. State of the Arg: Protein methylation at arginine comes of age.Cell 2001;106:5–8
  3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575
  4. Vallance P, Leiper J.Cardiovascular Biology of the Asymmetric Dimethylarginine: Dimethylarginine Dimethylaminohydrolase Pathway. Arterioscler Thromb Vas Biol 2004;24:1023-1030
  5. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme. NG,NG- dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem 1989;264: 10205–9
  6. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87: 99–105
  7. Yıldırım AO, Bulau P, Zakrzewicz D, Kitowska KE, Weissmann N, Grimminger et al. Increased protein arginine methylation in chronic hypoxia: Role of protein arginine methyltransferases. Am J Respir Cell Mol Biol.2006;35:436-43
  8. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995;117:237–238
  9. John P. Cooke. Does ADMA Cause Endothelial Dysfunction? Arterioscler Thromb Vasc Biol 2000;20:2032-2037
  10. Leiper JM, Santa MJ, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209–14
  11. Tran Cam TL, Fox MF, Vallance P, Leiper J. Chromosomal localization, gene structure and expression pattern of DDAH1: Comparison with DDAH2 and implications for evolutionary origins. Genomics 2000;68:101–105
  12. RH Böger. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research 2003; 59: 824-33
  13. Böger RH, Eyal SR. L-Arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005; 10(1): 14-23
  14. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639–46
  15. MacAllister RJ, Parry H, Kimoto M, Ogawa T,